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CCR5 Inhibition Prevents Cardiac Dysfunction in the SIV/Macaque
Model of HIV
Kathleen M. Kelly, DVM, PhD; Carlo G. Tocchetti, MD, PhD; Alexey Lyashkov, PhD; Patrick M. Tarwater, PhD; Djahida Bedja, MS;
David R. Graham, PhD; Sarah E. Beck, DVM; Kelly A. Metcalf Pate, DVM, PhD; Suzanne E. Queen, MS; Robert J. Adams, DVM;
Nazareno Paolocci, MD, PhD; Joseph L. Mankowski, DVM, PhD
Background-—Diastolic dysfunction is a highly prevalent cardiac abnormality in asymptomatic as well as ART-treated human
immunodeﬁciency virus (HIV) patients. Although the mechanisms underlying depressed cardiac function remain obscure, diastolic
dysfunction in SIV-infected rhesus macaques is highly correlated with myocardial viral load. As cardiomyocytes are not productively
infected, damage may be an indirect process attributable to a combination of pro-inﬂammatory mediators and viral proteins.
Methods and Results-—Given the diverse roles of CCR5 in mediating recruitment of leukocytes to inﬂammatory sites and serving
as a receptor for HIV entry into cells, we investigated the role of CCR5 in the SIV/macaque model of diastolic dysfunction.
We found that in SIV-infected macaques, CCR5 inhibition dramatically impacted myocardial viral load measured by qRT-PCR
and prevented diastolic dysfunction measured by echocardiography. Complementary in vitro experiments using ﬂuorescence
microscopy showed that CCR5 ligands impaired contractile function of isolated cardiomyocytes, thus identifying CCR5 signaling as
a novel mediator of impaired cardiac mechanical function.
Conclusions-—Together, these ﬁndings incriminate SIV/HIV gp120-CCR5 as well as chemokine-CCR5 interactions in HIV-
associated cardiac dysfunction. These ﬁndings also have important implications for the treatment of HIV-infected individuals: in
addition to antiviral properties and reduced chemokine-mediated recruitment and activation of inﬂammatory cells, CCR5 inhibition
may provide a cardioprotective beneﬁt by preventing cardiomyocyte CCR5 signaling. ( J Am Heart Assoc. 2014;3:e000874 doi:
10.1161/JAHA.114.000874)
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H IV-induced cardiac dysfunction presents a majorpotential health challenge for over 34 million infected
individuals. Although antiretroviral treatment (ART) has
reduced the incidence of cardiomyopathy that often accom-
panies development of AIDS, diastolic dysfunction remains
highly prevalent in asymptomatic as well as ART-treated HIV
patients.1–4 Overall cardiac function is depressed in HIV/AIDS
but the causes remain obscure. As cardiomyocytes are not
productively infected by HIV,5–9 damage to cardiomyocytes is
likely an indirect process that results from a combination of
pro-inﬂammatory mediators and viral proteins.5–11 Like HIV,
productive simian immunodeﬁciency virus (SIV) infection in
the myocardium is localized to macrophages. The SIV/
macaque model has facilitated the study of the pathophys-
iology of HIV-induced cardiac dysfunction, revealing that
diastolic dysfunction in SIV-infected rhesus macaques is
highly correlated with myocardial viral load.10,12,13
The chemokine CCL5 orchestrates recruitment of mono-
cyte/macrophages and resting/effector T cells to inﬂamma-
tory sites through binding to CCR5.14 In the heart, treatment
with an anti-CCL5 monoclonal antibody signiﬁcantly reduced
macrophage inﬁltration, infarct size, and post-infarction left
ventricular dysfunction in a mouse model of chronic ische-
mia.15 As CCR5 also serves as a receptor for HIV entry, CCR5
inhibition blocks HIV infection of cells expressing CCR5
including macrophages in the heart. Given these diverse roles,
CCR5 presents an attractive target to block both pro-inﬂam-
matory chemokine ligands of CCR5 (CCL3-5) as well as HIV
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gp120. In our studies, we evaluated whether treating SIV-
infected macaques with the CCR5 inhibitor maraviroc (MVC)
prevented diastolic dysfunction as well as whether isolated
cardiac ventricular myocytes expressed functional CCR5.
Materials and Methods
In Vivo Studies
Rhesus macaques (Macaca mulatta) were inoculated intrave-
nously with the macrophage-tropic clone SIV/17E-Fr and the
immunosuppressive swarm SIV/DeltaB670 as previously
described and treated with maraviroc (Pﬁzer, Inc. 200 mg
PO BID) beginning 24 days post-inoculation.16–18 MVC-treated
animals were euthanized at a study endpoint 180 days post-
inoculation, the mean survival time-point for a cohort of
untreated SIV-infected macaques.10 At euthanasia, all animals
were perfused with saline to remove blood and leukocytes
from the systemic vasculature. Hearts were immediately
harvested and samples were immersion ﬁxed in Streck Tissue
Fixative (Streck) or ﬂash frozen. Animal studies were approved
by the Johns Hopkins Institutional Animal Care and Use
Committee per Animal Welfare Act regulations and the USPHS
Policy on Humane Care and Use of Laboratory Animals.
For all studies, cardiac function was evaluated by echo-
cardiography performed by a single sonographer blinded to
animal infection and treatment status.10,19 Prior to inoculation,
cardiac function for all animals was evaluated by pulsed-wave
Doppler andM-mode echocardiogram in combination with a 2D
echocardiogram to record baseline myocardial velocities, wall
thickness and chamber dimensions under ketamine anesthesia
(5 to 10 mg/kg IM).10,19 Diastolic function was evaluated by
both mitral ﬂow and tissue Doppler echocardiography. Trans-
thoracic echocardiography was performed in the left lateral
decubital position using a Sequoia Acuson C256 ultrasound
machine equipped with 15 MHz linear transducer and ECG
monitor. Data were recorded over 5 cardiac cycles at a sweep
speed of 200 mm/s with simultaneous 3-limb lead electro-
cardiography stored digitally and measured (mean of 3 to 5
values) at the completion of each study. Measurements were
performed according to the recommendations set by the
American Society of Echocardiography.19 Each heart was
imaged in the 2D mode in the standard parasternal short,
parasternal long, 4- and 5-chamber axis views. Mitral inﬂow
and left ventricular outﬂow velocity-time interval traces were
obtained by placing the pulsed Doppler sample probe adjacent
to the anterior mitral valve leaﬂet tip in the left ventricle outﬂow
tract in the apical 4-chamber view. Tissue Doppler imaging
(TDI) was used to measure time intervals and myocardial
velocities. From the apical 4-chamber view, the sample volume
was placed in the ventricular myocardium immediately adja-
cent to the mitral annulus in either the septal or lateral wall.
Two to 3 pre-inoculation studies were performed on each
animal to establish individual baseline values. Echocardiogra-
phy evaluation was repeated immediately prior to euthanasia.
Alterations in cardiac performance were calculated by sub-
tracting terminal measurements from the mean baseline values
for MVC-treated rhesus macaques. SIV-infected rhesus
macaques treated with MVC were compared with a previously
reported cohort of dual-inoculated macaques and uninfected
controls.10 To account for any inﬂuence of aging on cardiac
function, comparisons were made to either baseline-to-termi-
nal values for untreated macaques surviving ≤180 days, or
changes from baseline-to-d180 echo measurement for maca-
ques surviving >180 days.
Immunostaining
To immunophenotype and measure myocardial macrophage
populations, single-label indirect immunohistochemistry was
performed on Streck-ﬁxed, parafﬁn-embedded 5 lm sections
of myocardium. Antigen retrieval consisted of microwaving
heart sections in sodium citrate buffer for 8 minutes.
Peroxide block was used on sections to quench endogenous
peroxidase activity followed by nonspeciﬁc background block
(Power Block, Biogenex). Sections were incubated with
primary antibody (CD68, 1:2000, clone KP1, DAKO; CD163,
1:10 000, clone Ber-MAC3, AbD Serotec) for 1 hour at room
temperature. Sections were then incubated sequentially in
biotinylated secondary multilink antibody and horseradish
peroxidase-labeled streptavidin or alkaline phosphatase linked
(Biogenex) depending on the chromagen with subsequent
detection using chromogenic substrate 3,30-diaminobenzidine
or vector red. In the heart, 15 nonoverlapping 2009 ﬁelds of
left ventricular myocardium were captured for analysis;
immunostaining for CD68 and CD163 in myocardium was
measured by quantitative digital image analysis.10
Isolated rhesus ventricular cardiomyocytes VCM were
rinsed with ice cold phosphate buffered saline PBS and then
ﬁxed with 4% paraformaldehyde (4°C). Fixed cells were rinsed
with PBS 0.2% Triton and then incubated with blocking solution
(PBS+5% BSA+2% goat serum+0.01% NaN3+0.2% Triton) for
30 minutes at room temperature. Cells were incubated with
anti-CCR5 antibody (BD 3A9, 1:50 in blocking solution) at 4°C
overnight. Cells were washed (PBS+Triton 0.2%), incubated in
the dark with Alexaﬂuor conjugated secondary antibody (1:200
in blocking solution) for 1 hour at room temperature. After
additional washes, cells were washed once with PBS and slides
were prepared with Prolong Gold (Life Technologies).
Viral Load Measurements
To evaluate SIV RNA levels, RNA was extracted from frozen
left ventricle; plasma virus was pelleted from 140 lL of
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plasma. Viral load was measured by qRT-PCR using primers to
quantitate SIV gag.10
Contraction Measurement and Whole Ca2+
Transients in Rhesus Macaque Ventricular
Myocytes
Single cell imaging experiments were performed on cardio-
myocytes isolated from 9 uninfected rhesus macaques. Hearts
collected from uninfected adult rhesus macaques euthanized
with intravenous pentobarbital sodium were collagenase
digested using a Langendorff apparatus. Via aortic cannula,
the hearts were perfused with isolation buffer solution
(in mmol/L: 116 NaCl, 26 NaHCO3 11 NaH2PO4, 1.6
MgSO47H2O, 5.4 KCl 5 Na-pyruvate; and glucose, 1 mg/mL)
to remove blood from the coronary system followed by
enzymatic digestion solution (1.2 U/mL trypsin, 1.2 U/mL
collagenase). Following mincing and ﬁltering (100 lm mesh),
the cell pellet was promptly resuspended in isolation buffer with
50 lmol/L Ca2+. After themyocytes were separated by gravity,
the supernatant was aspirated and myocytes were resus-
pended in Tyrode’s solution (in mmol/L: 140 NaCl, 10 HEPES, 1
MgCl2, 5 KCl; and glucose, 1 mg/mL pH 7.4) with 250 lmol/L
Ca2+. The ﬁnal cell pellet was suspended in 1 mmol/L Ca2+.
Single cell imaging experiments were performed immedi-
ately after isolation on cardiomyocytes loaded with the
membrane-permeable acetoxymethyl ester of Fura 2 (Fura 2-
AM 1 mmol/L with DMSO at room temperature). After allowing
for intracellular dye de-esteriﬁcation, ﬁeld stimulated (Warner
Instruments, 0.5 Hz) cells were imaged at room temperature
using an inverted ﬂuorescence microscope (Nikon). Single cell
recordings of sarcomeric contraction (measured by real-time
Fourier transform) and calcium transients (excitation of Fura-2
ﬂuorescence) were measured using an Ionoptix platform.
Myocytes were chosen for study according to previously
established criteria.20,21 Recordings were collected from single
cells over time while superinfused with Tyrode’s solution
1 mmol/L Ca2+. Isolated VCMs were probed for CCR5
expression using ligands of CCR5 and small molecule inhibitor
of CCR5, MVC. Cells were sequentially exposed to recombinant
human CCL5 (278-RN, R&D Systems) 100 nmol/L alone and
with 500 nmol/L of MVC (NIH/AIDS Reagent). As cells were
recorded over time, each cell served as its own control.
Statistical Analysis
SIV-infected rhesus macaques treated with MVC were com-
pared to a previously reported cohort of SIV-inoculated
macaques.10 To determine whether treatment with the CCR5
inhibitor maraviroc altered SIV-induced diastolic dysfunction,
the change from baseline to either terminal or d180
measurement (infected macaques surviving >180 days) was
compared between untreated SIV and maraviroc-treated SIV-
infected groups using the Mann-Whitney test. Similarly, to
determine whether maraviroc treatment altered myocardial
macrophage immune activation induced by SIV or SIV
replication in the myocardium, the amount of immunostaining
and SIV RNA in untreated SIV and maraviroc treated SIV
groups was compared using the Mann-Whitney test. Isolated
cardiomyocyte contraction and whole Ca2+ transient data
(mean of 20 cell contraction cycles/cell at steady state) were
compared using repeated measures analysis of variance
followed by individual group comparison by paired Student
t test. In all analyses, statistical signiﬁcance was deﬁned as
a P<0.05.
Results
Cardiac function in MVC-treated, SIV-infected rhesus maca-
ques was measured by echocardiography and compared with
untreated, SIV-infected macaques. While untreated, SIV-
infected macaques developed diastolic dysfunction,10 cardiac
function in MVC-treated, SIV-infected macaques was pre-
served, closely resembling cardiac function measured in
untreated, uninfected control animals (Table 1; Figure 1).
Untreated, SIV-infected macaques developed signiﬁcant pro-
longations in mitral inﬂow E wave deceleration time (MV DT)
over the course of infection; MVC treatment prevented MV DT
prolongation (Figure 1A). MVC treatment also prevented SIV-
induced changes in mitral valve isovolumetric relaxation time
(MV IVRT; Figure 1B). In addition, a comparison of terminal
MV measurements (rather than change over time) showed
that most SIV-infected animals (12/22; 54%) had E/A ratios
<1 whereas 5 of 6 SIV-infected macaques treated with MVC
had E/A ratios >1. Although the difference in terminal E/A
ratios between these 2 groups was not statistically signiﬁcant
(P=0.37), group sizes in these studies are much smaller than
cross-sectional cohort studies of HIV-infected individuals.3
Tissue-doppler derived indices of myocardial relaxation
were also preserved in MVC treated SIV-infected animals
(Figures 1C and 1D). Compared with untreated SIV-infected
macaques, lateral myocardial relaxation time (myoRT) and
septal myoRT were signiﬁcantly shorter in MVC-treated
animals and were similar to control macaques. SIV-induced
alterations in septal E’ also were prevented by MVC treatment
(P=0.016). Given that macaque thoracic anatomy and
relatively small heart size (ie, heart weight <50 g) are similar
to pediatric patients, the increased accuracy of septal imaging
compared to lateral imaging in macaques can be extrapolated
from pediatric echocardiography.
In addition to maintaining normal cardiac function, MVC
treatment signiﬁcantly decreased myocardial SIV RNA levels
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to below the limit of detection by qRT-PCR in 4 of 6 treated
macaques (Figure 2A). Plasma viral load in MVC-treated
animals was reduced by 1 to 2 logs after MVC treatment
(Figure 2B). As expected for antiretroviral monotherapy,
reduction of plasma viremia was transient and pronounced
differences in viral load were not apparent from day 90 post-
infection through terminal time points.
To determine whether MVC treatment altered macrophage
subpopulations in the myocardium, populations were
characterized by immunohistochemistry and digital image
analysis. Expression of CD163, a macrophage marker that
co-localizes with SIV proteins in the brain and the heart, was
signiﬁcantly lower in MVC-treated versus untreated SIV-
infected macaques (Figures 2C and 3).11,22 In contrast, MVC
treatment did not alter CD68 levels in infected macaques
(Figure 2D).
While increased CCR5 mRNA expression has been
reported in the failing myocardium, cell-speciﬁcity of CCR5
expression in the heart has not been characterized.23 Given
reports that cardiomyocytes express other cytokine and
chemokine receptors, we examined cardiomyocytes for CCR5
expression.8,24 Using double immunostaining for the cardio-
myocyte marker sarcomeric actin and CCR5 followed by
confocal microscopy, we identiﬁed CCR5 on macaque
cardiomyocytes (Figures 4A and 4B). To conﬁrm that CCR5
expressed on cardiomyocytes was functional, viable cardio-
myocytes were also isolated from adult rhesus hearts for
ex vivo studies. Freshly isolated rhesus macaque cardiomyo-
cytes were exposed sequentially to CCL5, then CCL5 in
combination with MVC (Figure 4C). The addition of CCL5 to
cardiomyocytes (n=18) signiﬁcantly reduced myocyte con-
tractility, decreasing sarcomeric fractional shortening by 27%
compared with basal contraction (Figure 4E). The subsequent
addition of MVC, a CCR5-speciﬁc inhibitor, reversed the
CCL5-induced decrease in myocyte contractility. Interestingly,
CCL5-induced changes in contraction were not coupled to
alterations in the amplitude of the whole Ca2+ transient (data
not shown).
In addition to reducing sarcomere contractility, CCL5
altered the kinetics of cardiomyocyte contraction but not
relaxation. CCL5 treatment increased the time to peak
contraction as compared with basal by 16%, indicating
Table 1. Echocardiographic Assessments of Change in Diastolic Function in Untreated SIV-Infected Macaques Versus Maraviroc-
Treated SIV-Infected Macaques
Control
Median (Interquartile Range)
SIV
Median (Interquartile Range)
SIV+MVC
Median (Interquartile Range) P Value*
Number of macaques 8 22 6
Mitral valve
IVRT, ms 4.50 (1.81 to 11.61) 8.95 (2.81 to 24.33) 4.50 (10.38 to 4.0) 0.0027
DT, ms 0.67 (13.00 to 15.45) 56.0 (14.67 to 94.3) 16.5 (25.50 to 4.25) 0.0013
E, m/s 0.01 (0.05 to 0.19) 0.06 (0.26 to 0.02) 0.03 (0.04 to 0.22) 0.061
A, m/s 0.04 (0.13 to 0.20) 0.08 (0.10 to 0.18) 0.09 (0.00 to 0.23) 0.575
E/A 0.05 (0.24 to 0.23) 0.3 (0.62 to 0.08) 0.09 (0.42 to 0.14) 0.370
TDI septal
myoRT, ms 4.33 (0.67 to 7.83) 11.5 (5.08 to 29.15) 4.50 (13.37 to 3.00) 0.0019
E’, ms 0.01 (0.01 to 0.01) 0.02 (0.04 to 0.00) 0.01 (0.00 to 0.03) 0.0161
A’, m/s 0.02 (0.04 to 0.23) 0.50 (0.76 to 0.2) 0.06 (0.35 to 0.00) 0.2824
E’/A’ 0.19 (0.40 to 0.23) 0.50 (0.76 to 0.2) 0.06 (0.35 to 0.00) 0.0310
E/E’ 0.81 (0.01 to 1.62) 0.34 (0.60 to 2.14) 0.82 (1.69 to 2.11) 0.8011
TDI lateral
myoRT, ms 3.45 (1.33 to 4.92) 20.67 (5.67 to 36.9) 4.00 (8.50 to 1.80) 0.0004
E’, ms 0.00 (0.04 to 0.03) 0.01 (0.05 to 0.02) 0.02 (0.02 to 0.02) 0.2971
A’, m/s 0.00 (0.01 to 0.04) 0.01 (0.00 to 0.04) 0.00 (0.10 to 0.03) 0.2976
E’/A’ 0.25 (0.55 to 0.21) 0.50 (0.76 to 0.03) 0.28 (0.42 to 0.65) 0.0468
E/E’ 5.02 (6.72 to 3.86) 2.51 (5.6 to 0.67) 0.65 (2.42 to 0.66) 0.1236
Table values are change from baseline calculated by subtracting the baseline mean from the terminal or day 180 PI value. A indicates late diastolic wave; DT, E wave deceleration time;
E, early diastolic wave; IVRT, isovolumetric relaxation time; MI, mitral inﬂow; MVC, maraviroc; myoRT, myocardial relaxation time; SIV, simian immunodeﬁciency virus; TDI, tissue Doppler
imaging.
*P value indicates Mann-Whitney for SIV vs SIV+MVC using Prism 6.
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an impaired cardiomyocyte ability to develop peak ten-
sion (Figure 4F). CCL5 did not signiﬁcantly change
myocyte relaxation rate (Figure 4G). However, myocyte
relaxation was faster in cardiomyocytes exposed to both
CCL5 and MVC as compared with basal relaxation times
(Figure 4G).
We then performed a reciprocal experiment in which
cardiomyocytes (n=17 cells) were ﬁrst treated with MVC
then exposed to a combination of both CCL5 and MVC
(Figure 4D). MVC treatment prior to CCL5 addition blocked
the previously observed CCL5 effect and did not signiﬁcantly
alter either sarcomere contraction or the whole Ca2+
transient. Moreover, MVC treatment alone did not alter the
Figure 2. Maraviroc (MVC) reduces viral replication in heart and
plasma, and macrophage activation in myocardium. A, Simian
immunodeﬁciency virus (SIV) RNA levels in the heart were
signiﬁcantly lower in MVC-treated SIV-infected macaques vs
untreated SIV-infected macaques. B, Mean plasma viral load over
the course of infection in MVC-treated vs untreated SIV-infected
macaques showed an initial 1 to 2 log decrease in SIV RNA. C,
Total immunostaining for CD163+ macrophages was signiﬁcantly
lower in MVC-treated vs untreated SIV-infected macaques, similar
to immunostaining levels in uninfected control macaques (see
Figure 3). D, In contrast, MVC treatment did not reduce
myocardial immunostaining for CD68 in SIV-infected macaques.
Mann-Whitney; bars represent median values.
Figure 1. Maraviroc (MVC) therapy preserves diastolic function
in SIV-infected macaques. A, MVC-treated SIV-infected macaques
had preserved mitral inﬂow E wave deceleration times (MV DT). B,
The median MV isovolumetric relaxation time (IVRT) was also
signiﬁcantly lower with MVC treatment vs untreated SIV-infected
macaques. MVC also prevented increases in tissue Doppler (TDI)-
derived lateral myocardial relaxation time (myoRT, C) and septal
myoRt (D) as compared to untreated SIV-infected macaques.
Analyses represent Mann–Whitney tests; bars represent median
values. SIV indicates simian immunodeﬁciency virus.
Figure 3. Maraviroc treatment reduced SIV-induced upregulation of macrophage expression of CD163 in myocardium. A, Scattered CD163-
immunopositive macrophages (arrow, brown cytoplasm) were present in the myocardium of uninfected control animals. B, The number and cell
size of interstitial and perivascular CD163-positive macrophages increased with SIV infection. C, Maraviroc treatment prevented upregulation of
CD163 in myocardium of SIV-infected macaques. Bar=100 lM.
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Figure 4. CCL5 decreases cardiomyocyte contractility via CCR5. Confocal microscopy showing
expression of (A) CCR5 (red) on isolated adult rhesus macaque ventricular cardiomyocyte (RM VCM)
merged with (B) sarcomeric actin (green). C, Representative twitch traces for VCM sequentially exposed to
human recombinant CCL5 (100 nmol/L), then CCL5 (100 nmol/L) with maraviroc (MVC, 500 nmol/L).
Compared to basal conditions (grey, left), CCL5 decreased contractility, shown by the reduced, ﬂattened
twitch amplitude (red, middle). The CCL5-induced decline in contractility was reversed by subsequent
addition ofMVCwith CCL5 (green, right). D, Representative twitch traces for reciprocal experiments showing
VCM sequentially exposed to MVC (500 nmol/L) followed by a combination CCL5 (100 nmol/L) and MVC
(500 nmol/L). Addition of MVC (blue, middle) did not alter contraction from basal (grey, left). Furthermore,
addition of MVC prior to MVC+CCL5 (turquoise, left) prevented CCL5-induced changes in contractility with
twitch traces unchanged from basal. E, Summary data for RM VCM exposed to CCL5 (100 nmol/L) followed
by MVC (500 nmol/L) with CCL5 (100 nmol/L). CCL5 signiﬁcantly decreased fractional shortening
compared to basal. Subsequent addition of MVC modulated the CCL5 effect towards basal shortening.
F, CCL5 signiﬁcantly increases the time from basal to 50% peak sarcomere length (t to pk) compared to basal
conditions. Subsequent CCL5+MVCmodulated t to pk shortening towards basal conditions. G, CCL5 did not
signiﬁcantly change the time from peak shortening to 50% baseline (t to bl) compared to basal conditions
although t to bl in cells treated with CCL5+MVC was shorter than both basal and CCL5 treatment. Paired
t-tests, mean value indicated by the top of bar with bars representing standard error.
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rate of cardiomyocyte contraction or relaxation (data not
shown).
Discussion
The echocardiographic data show that CCR5 inhibition
prevented diastolic dysfunction in SIV infection, demonstrat-
ing clearly that CCR5 ligands play important roles in cardiac
dysfunction. In addition to maintaining normal cardiac func-
tion, maraviroc treatment signiﬁcantly decreased myocardial
SIV RNA levels in treated infected macaques. As reduction of
plasma viremia was transient, the major sustained impact of
MVC treatment on viral replication was in the heart rather
than in blood.
Our previous studies found that myocardial macrophage
activation was necessary for development of diastolic
dysfunction.10 Expression of CD163, a macrophage marker
that co-localizes with SIV protein, was signiﬁcantly lower in
MVC-treated versus untreated SIV-infected macaques while
CD68 levels were unchanged. The strong positive correlation
we previously found between myocardial expression of CD163
and CD68 in SIV-infected macaques was not maintained in
MVC-treated SIV-infected macaques. Together, these data
show that the anti-inﬂammatory impact of MVC treatment is
focused on speciﬁc macrophage subpopulations in the heart
and further suggests an important role for CD163+ macro-
phages in particular in the development of HIV-induced
cardiac dysfunction. Additional studies are necessary to
establish the immunomodulatory impact of CCR5 inhibition on
myocardial macrophage subpopulations.
Our functional data from isolated viable macaque cardio-
myocytes demonstrate that CCL5 binding to CCR5 alters
cardiomyocyte mechanical function without inducing
alterations in the amplitude of the whole Ca2+ transient.
CCL5-induced changes in fractional shortening can be reversed
or prevented with CCR5 inhibition, demonstrating that MVC
treatment can prevent CCR5-mediated cardiomyocytemechan-
ical dysfunction. The ﬁnding that CCL5-induced changes in
cardiac cell contractility and relaxation develop in the absence
of salient modiﬁcations of the whole Ca2+ transient suggests
that CCL5 binding to CCR5 desensitizes myoﬁlament proteins
to the effects produced by physiological levels of intracellular
Ca2+. Studies in rodent models have also suggested that HIV
gp120 can induce desensitization of myoﬁlaments.9
Although HIV and SIV use the chemokine receptor CCR5 to
gain entry to susceptible cell types including macrophages
inﬁltrating the myocardium, binding and signaling through
chemokine receptors CXCR4 or CCR5 can occur independent
of viral entry.25–27 HIV gp120 signaling through chemokine
receptors resembles the action of cognate chemokine ligands,
contributing to the deleterious outcomes associated with
sustained immune activation. As conformationally appropriate
trimeric SIV gp120 is unavailable, we used CCL5 to emulate
SIV gp120 binding to cardiomyocyte CCR5. The dramatic
impact of MVC treatment on both myocardial viral load and
prevention of diastolic dysfunction in SIV-infected macaques
implicates SIV gp120-CCR5 as well as chemokine-CCR5
interactions in cardiac dysfunction.
MVC treatment in HIV patients is limited by the require-
ment to characterize HIV co-receptor usage prior to starting
MVC treatment.28–30 Widespread use of CCR5 antagonists for
HIV is further hampered by concerns over drug resistance and
emergence of HIV strains utilizing chemokine receptor CXCR4
due to selective pressure. Nonetheless, MVC is unique
because, in addition to blocking HIV entry, it has substantial
immunomodulatory effects including dampening chemokine
signaling that mediates monocyte-macrophage recruitment
through CCR5.31 Our studies show a novel potential beneﬁcial
role for CCR5 inhibitors in preserving cardiomyocyte contrac-
tility in the face of CCR5 ligands.
As survival of HIV-infected patients increases, additional
cardiac insults including aging and coronary artery disease
will be superimposed upon primary HIV cardiac damage. The
cumulative impact may be profound, highlighting the need for
novel therapeutic approaches such as addition of CCR5
inhibitors to prevent early and ongoing cardiac damage. This
study revealed 2 major ﬁndings: (1) in vivo CCR5 inhibition
prevented diastolic dysfunction in SIV-infected macaques and
(2) in vitro experiments showed that CCR5 ligands impair
contractile function of cardiomyocytes, thus identifying CCR5
signaling as a novel mediator of impaired cardiac mechanical
function. Together, these ﬁndings illustrate that therapeutic
CCR5 inhibition offers multiple advantages for HIV treatment.
In addition to antiviral properties and reduced chemokine-
mediated recruitment and activation of inﬂammatory cells,
CCR5 inhibition provides an additional cardioprotective ben-
eﬁt by preventing cardiomyocyte CCR5 signaling. In disease
settings associated with chronic inﬂammation, including post-
infarction, sustained production of CCR5 ligands can induce
CCR5-mediated cardiomyocyte functional impairment, extend-
ing the signiﬁcance of our ﬁndings beyond HIV.15
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